Considering that TREM2-expressing TAMs are abundant in CRC and associated with poor prognosis and immune suppression, we hypothesized that targeting TREM2 in TAMs could augment therapeutic effect of STING agonist MSA-2 while minimizing systemic toxic side effects. The gene discussed is STING1; the disease is colorectal carcinoma.